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Summary. Purpose: To evaluate the expression of NF-
κB pathway genes in total bone marrow samples
obtained from MM at diagnosis using real-time
quantitative PCR and to evaluate its possible correlation
with disease clinical features and survival. Material and
methods: Expression of eight genes related to NF-κB
pathway (NFKB1, IKB, RANK, RANKL, OPG, IL6,
VCAM1 and ICAM1) were studied in 53 bone marrow
samples from newly diagnosed MM patients and in
seven normal controls, using the Taqman system. Genes
were considered overexpressed when tumor expression
level was at least four times higher than that observed in
normal samples. Results: The percentages of
overexpression of the eight genes were: NFKB1 0%, IKB
22.6%, RANK 15.1%, RANKL 31.3%, OPG 7.5%, IL6
39.6%, VCAM1 10% and ICAM1 26%. We found
association between IL6 expression level and
International Staging System (ISS) (p=0.01), meaning
that MM patients with high ISS scores have more chance
of overexpression of IL6. The mean value of ICAM1
relative expression was also associated with the ISS
score (p=0.02). Regarding OS, cases with IL6
overexpression present worse evolution than cases with
IL6 normal expression (p=0.04). Conclusion: We
demonstrated that total bone marrow aspirates can be
used as a source of material for gene expression studies
in MM. In this context, we confirmed that IL6
overexpression was significantly associated with worse
survival and we described that it is associated with high
ISS scores. Also, ICAM1 was overexpressed in 26% of
cases and its level was associated with ISS scores. 
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Introduction
Multiple myeloma (MM) is a B-cell malignancy
characterized by expansion of monoclonal plasma cells
in bone marrow and is associated with osteolytic bone
disease (Berenson et al., 2001). Currently, MM remains
as an incurable disease despite treatment with
conventional and/or high-dose chemotherapy (Kyle and
Rajkumar, 2004). Therefore, novel therapies that target
both tumor cells and bone marrow microenvironment are
urgently needed to overcome resistance to conventional
therapies and improve MM patient’s outcome (Chauhan
et al., 2005a).
Members of the nuclear factor-kappa B (NF-κB)
transcription factor family play an important role in the
pathogenesis of lymphoid malignancies (Berenson et al.,
2001) and also have a role in chemoresistance of a
variety of tumors (Bharti et al., 2004). In MM, NF-κB is
a key regulator, promoting expansion of tumor cells in
the bone marrow milieu and is involved in the control of
various cellular processes, such as immune and
inflammatory responses, cell growth, bone resorption,
and apoptosis. NF-κB is bound to I-κB in the cytoplasm
and its activation occurs through proteasome-mediated
degradation of I-κB (Mitsiades et al., 2002; Rajkumar et
al., 2005). This allows NF-κB to translocate to the
nucleus and bind to specific cis-acting consensus
sequences (κB sites) located in the regulatory region of
inducible genes, including cytokines (TNFα, IL-2, IL-6,
IL-8, α-interferon), adhesion molecules (intercellular
adhesion molecule-1 or ICAM-1, vascular cell adhesion
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molecule-1 or VCAM-1), genes involved in the
regulation of apoptosis (TRAF1/2, cIAP1 and 2, TNRF1,
IκB) or response to NF-κB and those involved in cell
cycle regulation and proliferation (cyclin D1, MYC, p53,
Rb) (Willis and Dyer, 2000). Also, adhesion of MM cells
to bone marrow stromal cells triggers NF-κB-mediated
transcription and secretion of interleukin-6 (IL-6), which
has an important role in enhancing growth or prolonging
survival of MM cells (Bharti et al., 2004; Roodman,
2004).
Since MM cells have altered or defective cell cycle
proteins, leading to an increased proliferation rate and
increased accumulation of damaged proteins, they have
higher dependency on the proteasomal degradation
process. Therefore, proteasome inhibitors, such as
bortezomib, down-regulate NF-κB activation and related
cytokine production, thereby enhancing the cytotoxic
effects of bortezomib-based chemotherapy (Chauhan et
al., 2005b).
Genes important to MM osteolytic lesions
pathogenesis also participate in the NF-κB pathway
(Giuliani et al., 2006). The bone marrow micro-
environment plays a critical role in the formation of
osteoclasts, through production of essential cytokines for
osteoclasts biology (Roodman, 2004). Osteoclast
precursors express RANK, a member of the tumor
necrosis factor receptor superfamily. RANKL binds the
RANK receptor and induces the differentiation of
osteoclasts through the NF-κB and Jun N-terminal
kinase (JNK) pathways (Roodman, 2004). Also, in the
bone marrow microenvironment, osteoblasts secrete
osteoprotegerin (OPG), which acts as a decoy receptor
and blocks RANKL, preventing RANK activation (Sezer
et al., 2003).
The outcome of patients with MM is highly variable
because there is a heterogeneity in both myeloma cell
biology and host factors (Berenson et al., 2001). A new
staging system, based on serum levels of ß2-
microglobulin and serum albumin at diagnosis, was
established as the International Staging System (ISS)
and seems to reflect the genetic-molecular background
in MM (Greipp et al., 2005). Therefore, the aim of this
study was to evaluate the expression of NF-κB pathway
genes in MM patients by real-time quantitative PCR and
its possible correlation with clinical features, including
ISS and survival. 
Materials and methods
Patients and controls
Between June 2002 and April 2006, we obtained
total bone marrow aspirates from 53 newly diagnosed
MM patients, referred to the Department of Hematology
and Hemotherapy of Federal University of São Paulo,
UNIFESP, São Paulo, Brazil. Patients were included
after diagnosis of MM based on The International
Working Group Criteria (The International Myeloma
Working Group, 2003) and after signature of informed
consent. Bone marrow biopsy and aspiration were
obtained from the posterior iliac crest. Only patients
with no previous chemotherapy, corticosteroids or
bisphosphonates were included. MM patients were
classified according to Durie-Salmon staging system and
ISS (Greipp et al., 2005). Seven healthy controls were
used, being six bone marrow aspirates from allogeneic
transplant donors and one pool of 10 bone marrow
samples from Clontech (Palo Alto, CA, USA). Written
informed consent was obtained from all patients and
controls, and the study was approved by our Institution
Ethical Committee. Clinical characteristics of the MM
patients are shown in Table 1.
Pilot study
Tumor plasma cells were isolated from 12 total bone
marrow aspirates obtained from MM cases at diagnosis
through magnetic sorting of CD-138 (syndecan-1)
positive cells using MACS system (Magnetic Cell
Sorting of Human Cells, Miltenyi Biotec, Bergisch
Gladbach, Germany). Normal plasma cells were
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Table 1. Clinical characteristics of 53 MM patients included at diagnosis.
Clinical characteristics N %
Age: median (range)-62 years (27-80)
<62 years 25 47
≥ 62 years 28 53
Sex
Male 31 58.5
Female 22 41.5
M-component type
IgG kappa or lambda 30 56.6
IgA kappa or lambda 13 24.5
Light chain only 10 18.8
Durie Salmon stage
IA 2 3.8
IIA 2 3.8
IIIA 32 60.4
IIIB 17 32.1
ISS
1 10 18.9
2 18 34
3 21 39.6
Missing data 4 7.5
Bone marrow plasma cells (median:80%)
<50% 8 15.1
50-79% 13 24.5
≥ 80% 32 60.4
Treatment
Conventional chemotherapy* 46 86.8
High dose melphalan + ASCT** 5 9.4
Allogeneic transplant 2 3.8
Total 53 100
*Conventional chemotherapy: VAD or Melphalan+Prednisone or
Thalidomide+dexamethasone. **High dose melphalan and autologous
stem cell transplantation (ASCT) after induction treatment.
obtained from three pools of palatine tonsils (children
submitted to tonsillectomy) and two bone marrow
aspirates from allogeneic transplant donors through
magnetic sorting of CD-138 (syndecan-1) positive cells.
Ten out of 12 MM bone marrow aspirates had more than
50% of plasma cells. The magnetic sorting method was
able to separate tumor plasma cells from other bone
marrow cells achieving a high degree of purification
(>85%), confirmed by flow cytometry. 
Genes selected for study
We chose eight genes related to the NF-κB pathway
for this study. They are related to cellular proliferation
(NFKB1, NFKBIA (IKB), IL6), bone disease (RANK,
RANKL, OPG) and interaction between plasma cells and
stromal cells (VCAM1, ICAM1) (Table 2). 
RNA extraction and cDNA synthesis
Bone marrow aspirates were obtained in EDTA in
the same place where bone marrow biopsies were
performed. Two-hundred µ L of total bone marrow
aspirates were submitted to erythrocytes lysis. The pellet
was homogenized in 1mL of TRIzol reagent (Invitrogen,
Carlsbad, CA) and maintained at -70°C until total RNA
was extracted. The RNA was recovered from the
aqueous phase by ethanol precipitation and the pellets
were dissolved in 30 µL of DEPC water. First-strand
cDNA synthesis, primed with oligo(dT) and 2 µg of
RNA template, was reverse transcribed (Superscript II,
Invitrogen, Carlsbad, CA, USA). After cDNA synthesis,
the expression of Notch2 was determined in all samples
and the quality of samples was assessed by 2% agarose
gel electrophoresis. 
Real-time quantitative PCR
Gene expression was evaluated by real-time
quantitative PCR (RQ-PCR) on ABI PRISM® 7000
Sequence Detection System Instrument (Applied
Biosystems, Foster City, CA, USA). Primers and probes
were obtained through Assays-by-Design Service
(Applied Biosystems). Each cDNA sample was
normalized using glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) gene based on previous
publications (Condomines et al., 2007; Gonzalez-Paz et
al., 2007). TaqMan Universal PCR Master Mix (Applied
Biosystems) was used to perform RQ-PCR and assays
were reproduced in triplicate. Blank and positive
controls were run in parallel to verify amplification
efficiency. Genes were considered differentially
expressed in tumor samples when their expression levels
showed at least a 4-fold increment or decrease in
comparison to average expression in normal samples.
Statistical analysis
Associations between the studied variables were
tested by the Pearson Chi-Square Test (χ2). T-Test or
ANOVA were used to perform mean comparisons.
Overall survival (OS) time was calculated from the date
from diagnosis of MM until death or last follow-up.
Survival curves of the eight studied genes were obtained
separately according to their expression level
(overexpression, normal expression and under-
expression). Actuarial probabilities of OS were
estimated according to the Kaplan-Meier method and the
curves were compared using the log-rank test. The level
of significance for all statistical tests was 5%. 
Results
Our initial analyses were performed in a restricted
group of 12 MM patients to compare the expression of
the eight selected genes in total bone marrow aspirates
and their respective purified tumor plasma cells. Median
tumor plasma cell infiltration in this small group of bone
marrow aspirates was 47% (ranging from 10 to 80%).
Also, ten out of 12 cases had more than 50% of plasma
cells infiltration assessed by bone marrow biopsy
performed in the same place of aspirate. We found
underexpression of RANKL, OPG and VCAM1 in 100%,
83.3% and 92% of purified tumor plasma cells,
respectively. On the other hand, expression of IL6
showed 58.3% of concordance between the two sources
of RNA (total bone marrow aspirate and purified tumor
plasma cells) (r=0.838) (Table 3). This pilot study
showed that IL6 overexpression was detected in both
sources of samples, and genes related to bone marrow
microenviroment were underexpressed (OPG, RANKL,
VCAM1) when only purified plasma cells were
evaluated. Therefore, we decided to study these eight
NF-κB pathway genes using total bone marrow aspirates
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Table 2. Nuclear factor-kappa B pathway studied genes in MM patients.
NFKB1 Nuclear factor-kappa B (p105) NM_003998 Transcription regulator of several biological functions
IKB (NFKBIA) Nuclear factor-kappa B Inhibitor NM_020529 Inhibits NF-κB in cytoplasm
RANK NFKB activator NM_003839 Osteoclast differentiation
RANKL RANK ligand NM_003701 Osteoclast activation and differentiation
OPG Osteoprotegerin NM_002546 Negative regulator of bone resorption
IL6 Interleukin-6 NM_000600 MM cells proliferation
VCAM1 Vascular cell adhesion molecule NM_001078 Cellular adhesion and sign transduction
ICAM1 Intercellular adhesion molecule NM_000201 Cellular adhesion
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Table 3. Expression of NF-κB genes in 12 total bone marrow samples and respective purified MM plasma cells. Genes were considered differentially
expressed in tumor samples when their expression levels showed at least a 4-fold increment or decrease in comparison to normal samples.
Case
%BM PC RANK RANKL OPG NFKB1 IKB IL6 VCAM1 ICAM1
Aspirate Biopsy BM PC BM PC BM PC BM PC BM PC BM PC BM PC BM PC
17 70 90
20 28 98
22 20 95
23 60 95
24 10 10
27 52 80
28 50 70
32 33 50
34 10 30
35 53 70
44 80 90
46 43 70
BM: bone marrow samples; PC: plasma cells; White: Underexpression; Gray: Normal expression; Black: Overexpression.
Table 4. Correlation between gene expression level and ISS in total bone marrow aspirates of MM patients. 
Gene expression ISS 1 ISS 2 ISS 3 p value
RANK Underexpression 1(10) 0(0) 0(0) 0.181
Normal expression 9(90) 14(77.8) 18(85.7)
Overexpression 0(0) 4(22.2) 3(14.4)
Total 10(100) 18(100) 21(100)
RANKL Underexpression 1(14.3) 1(5.9) 1(5) 0.817
Normal expression 5(71.4) 11(64.7) 12(60)
Overexpression 1(14.3) 5(29.4) 7(35)
Total 7(100) 17(100) 20(100)
OPG Underexpression 1(10) 4(22.2) 8(38.1) 0.485
Normal expression 8(80) 13(72.2) 11(52.4)
Overexpression 1(10) 1(5.6) 2(9.5)
Total 10(100) 18(100) 21(100)
NFKB1 Underexpression 0(0) 0(0) 0(0) (a)
Normal expression 10(100) 18(100) 21(100)
Overexpression 0(0) 0(0) 0(0)
Total 10(100) 18(100) 21(100)
IKB Underexpression 0(0) 0(0) 0(0) 0.162
Normal expression 10(100) 13(72.2) 15(71.4)
Overexpression 0(0) 5(27.8) 6(28.6)
Total 10(100) 18(100) 21(100)
IL6 Underexpression 0(0) 0(0) 4(19) 0.010
Normal expression 9(90) 7(38.9) 9(42.9)
Overexpression 1(10) 11(61.1) 8(38.1)
Total 10(100) 18(100) 21(100)
IL6 Under and normal expression 9(90) 7(38.9) 13(61.9) 0.029
Overexpression 1(10) 11(61.1) 8(38.1)
Total 10(100) 18(100) 21(100)
VCAM1 Underexpression 1(11.1) 1(5.6) 4(21) 0.483
Normal expression 7(77.8) 15(83.3) 13(68.4)
Overexpression 1(11.1) 2(11.1) 2(10.6)
Total 9(100) 18(100) 19(100)
ICAM1 Underexpression 0(0) 0(0) 0(0) 0.112
Normal expression 9(100) 14(77.8) 11(57.9)
Overexpression 0(0) 4(22.2) 8(42.1)
Total 9(100) 18(100) 19(100)
(a) No statistics are computed because NFKB1 is a constant.
to collect simultaneous information regarding
microenvironment and tumor cells status. 
We studied the expression of the eight selected genes
in 53 total bone marrow samples and in seven normal
samples. Percentages of overexpression of the eight
studied genes were: NFKB1 0%, IKB 22.6%, RANK
15.1%, RANKL 31.3%, OPG 7.5%, IL6 39.6%, VCAM1
10% and ICAM1 26%. We correlated each gene
expression level (overexpression, normal expression and
underexpression) to bone marrow plasma cells
percentage and to ISS system (Table 4). In 53 studied
patients, only eight had less than 50% of plasma cells in
bone marrow biopsy and we did not find a correlation
between gene expression level and the number of plasma
cells at diagnosis. However, we found an association
between IL6 expression level and ISS (p=0.01), meaning
that patients with advanced stage disease have more
chance of presenting IL6 overexpression.
Mean values of gene expression were compared in
the three ISS categories. The mean value of ICAM1
relative expression was associated with ISS score
(p=0.02), i.e., cases classified as ISS 3 had higher levels
of ICAM1 expression (Fig. 1). 
In this study, follow-up varied from 4 days to 60
months (median=20 months). Median overall survival
(OS) for the entire group was 21 months. We did not
find any statistical difference between survival curves of
clinical parameters. We found a statistical difference
between IL6 expression level and survival, i. e., cases
with IL6 overexpression presented worse evolution than
cases with IL6 normal expression (p=0.04). Surprisingly,
cases with underexpression of IL6 had shorter survival
than cases with normal expression of IL6 (p=0.003).
These results were confirmed after exclusion of patients
submitted to autologous stem cell transplantation (Fig.
2). Besides IL6, we analyzed survival curves comparing
IKB (p=0.83), RANK (p=0.44), RANKL (p=0.07), OPG
(p=0.31), VCAM1 (p=0.27) ICAM1 (p=0.95) expression
level and we did not find any statistical difference
among survival curves. 
Discussion 
Extensive studies have demonstrated the importance
of the bone marrow microenvironment in promoting cell
growth, survival and drug resistance in MM. They have
already proposed several therapies based on targeting the
MM cells and their interactions in bone marrow milieu
(Richardson et al., 2007). To be effective, ideal therapies
must include the molecular mechanisms underlying the
protective effects of the bone marrow microenvironment
on MM cells (Richardson et al., 2007). Thus, due to the
importance of bone marrow microenvironment to MM
pathogenesis we conducted a pilot study to assess which
would be the best source of RNA for these eight NF-κB
pathway gene expression studies. In this small group of
patients we did not find concordance between NF-κB
pathway genes expression in bone marrow aspirates and
isolated plasma cells, except IL6. We concluded that
isolated analyses of purified MM plasma cells would
miss information regarding the studied genes expressed
predominantly by other bone marrow cells, such as
stromal cells. Of course it was possible because we
studied a selected number of genes and it cannot be
extrapolated to more complex global gene expression
analysis methods, such as SAGE or microarrays. Also,
the majority of patients included in this study had more
than 50% of plasma cells infiltration in bone marrow.
This characteristic probably reduced the risk of
underexpression of a given gene due to low percentage
of plasma cell infiltration. Therefore, because of
underexpression of RANKL, OPG and VCAM1 in
isolated plasma cells, we decided to study total bone
marrow aspirates. In the literature, there is no consensus
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Fig. 2. Survival curves according to IL6 expression level at diagnosis
and autologous stem cell transplant (ASCT) in 53 MM patients (p=0.04).
There was no underexpression case with ASCT.Fig. 1. Relative expression of gene ICAM1 according to ISS 1, 2 and 3in total bone marrow aspirates of MM patients.
about the cellular origin (stromal/osteoblastic or MM
cells) of RANKL increased biological activity in MM
(Haaber et al., 2007). Another possible strategy to be
adopted in future in this kind of study would be to
examine the expression of the same genes in two
populations, separately: CD 138-positive population
(obtained by magnetic sorting) and CD 138-negative
population (flow through). 
According to the Durie & Salmon staging system,
92.5% of patients were classified as stage III, reflecting
a possible delay in suspecting MM before patients are
referred to our institution - a tertiary service in an
underdeveloped country. Unfortunately, in this cohort of
consecutive patients, we did not have samples of
monoclonal gammopathy or early stage MM to compare
the results obtained with MM stage III. However, we
were able to classify our patients better through ISS
staging system: 34% were ISS 2 and 39.6% ISS 3. After
60 months of maximum follow-up, median overall
survival was 21 months for our entire group (31.5
months for ISS 1, not reached for ISS 2 and 13 months
for ISS 3). 
IL6 was overexpressed in 39.6% of our patients and
it was significantly associated to advanced-stage disease.
IL-6 was originally characterized as a cytokine that
causes the terminal differentiation of activated B-cells
into immunoglobulin-secreting cells and was then shown
to be a major growth and survival factor for MM cells.
More recently, IL-6 has been shown to stimulate the
growth of plasmablasts and to protect early plasma cells
from apoptosis, allowing their terminal differentiation
into plasma cells (Brocke-Heidrich et al., 2004). 
Besides the importance of IL6, the analyses of the
genes of NF-κB in MM total bone marrow samples
showed overexpression of at least three more genes:
RANKL in 31.3%, IKB in 22.6% and ICAM1 in 26% of
cases. Therefore, ICAM1 seems to have some new
potential as a therapeutic target in MM, since RANKL
and IKB have been inhibited and stabilized by
denosumab (monoclonal antibody against RANKL)
(Body et al., 2006) and bortezomib, respectively
(Richardson et al., 2005; Mitsiades et al., 2006).
Furthermore, the mean value of ICAM1 relative
expression was associated with ISS scores, i.e., cases
classified as ISS 3 had higher levels of ICAM1 ,
confirming its importance in MM aggressiveness. Since
this molecule stabilizes NF-κB, we could hypothesize
that overexpression of IKB could confer better prognosis
to MM patients. Although we found overexpression of
IKB in 22.6% of patients, this group did not correlate
with ISS stage (p=0.162) or survival (p=0.83), when
compared to normal or underexpression group.
We did not find any statistical difference between
survival curves of clinical parameters. Probably this
happened because the majority of patients presented
advanced stage disease (stage III). IL6 overexpression
was related to worse survival in our study and confirms
its participation in myeloma progression, regulating
growth and survival of tumor cells. However, there was
no difference in survival between patients with IL6
underexpression and overexpression. This fact probably
occurred because all patients with IL6 underexpression
were ISS stage 3. Therefore, other factors related to
worse prognosis must be influencing the unfavorable
outcome of such MM patients, besides IL6 expression. 
Recently, Annunziata et al. (2007) described diverse
genetic and epigenetic mechanisms, such as alteration of
NIK, TRAF3, CYLD, BIRC2/BIRC3, CD40, NFKB1, or
NFKB2, leading to NF-κB activity in myeloma cell lines
and patient samples. Most primary MM patient samples
had evidence of NF-κB pathway activation, suggesting
that therapeutic strategies targeting the classical NF-κB
pathway should be pursued. Their work showed that
targeted disruption of classical NF-κB signaling with a
small-molecule inhibitor of IKκb blocked myeloma cell
proliferation and induced cell death. Their recent
findings corroborate the importance of the NF-κB
pathway as a target for MM therapy, justifying all the
efforts to better understand this pathway. 
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